Vectura Group plc today announces its Preliminary Results for the year ended 31 December 2020. For full details, please click here.
Commenting on the results, Will Downie, Chief Executive Officer of Vectura, said:
“The business has performed well during 2020, delivering financial performance ahead of expectations. We are pleased with the progress we have made against our inhalation CDMO strategy, signing 18 deals during 2020, with £3.0m revenue recognised in the second half of the year.
“After the positive outcome of the appeal in the GSK US patent litigation, initial proceeds were received by Vectura in January 2021. Following a review of the Group’s allocation priorities, we have today announced that the Board has approved, in principle, a special dividend of approximately £115m which is intended to be paid to shareholders during 2021.
“This is an exciting time for the Group and with continued momentum expected from our CDMO business, we look forward to a positive 2021.”
Vectura’s CEO Will Downie shares his thoughts on our performance in 2020 and the progress we’ve made transforming to become a market leading inhalation CDMO.
Analyst webcast and conference call today
Vectura will present its Preliminary Results via live webcast today from 9.30am to 10.30am GMT. There will be a simultaneous live conference call.
The live webcast and the presentation slides can be accessed on Vectura’s website: https://www.vectura.com/investors/presentations-and-webcasts
Dial-in details are:
Participant local dial-in: +44 (0) 207 192 8338
Participant free phone dial-in: +44 (0) 800 279 6619
Participant code: 5263586